abatacept
Orencia
Pharmaceutical company: Bristol-Myers Squibb
NEW INDICATION & DOSAGE
Prophylaxis of acute graft-versus-host disease, in combination with a calcineurin inhibitor and methotrexate, in patients undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor
Adults and children age 6 and older: 10 mg/kg dose (maximum dose 1,000 mg) IV infusion over 60 minutes on the day before transplantation, followed by a dose on days 5, 14, and 28 after transplant.
Children ages 2 to less than 6: 15 mg/kg dose IV infusion over 60 minutes on the day before transplantation, followed by 12 mg/kg on days 5, 14, and 28 after transplant.
Released: February 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
budesonide
Tarpeyo
Pharmaceutical company: Calliditas Therapeutics
NEW AVAILABLE FORM
Delayed-release capsules: 4 mg
INDICATION & DOSAGE
Proteinuria in patients with primary immunoglobulin A nephropathy at risk for rapid disease progression
Adults: 16 mg PO daily in the morning at least 1 hour before a meal.
Adjust-a-dose: Reduce dose to 8 mg daily for 2 weeks before discontinuing the drug.
Released: February 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
carfilzomib
Kyprolis
Pharmaceutical company: Amgen, Inc.
NEW INDICATION & DOSAGE
Relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj and dexamethasone after one to three prior lines of therapy
Adults: For twice-weekly 20/56 mg/m2 regimen, give as a 30-minute IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle in combination with subcut daratumumab and hyaluronidase-fihj, and dexamethasone until disease progression or unacceptable toxicity occurs. Initially, give 20 mg/m2 on cycle 1, days 1 and 2. If tolerated, escalate to 56 mg/m2 on cycle 1, day 8 and thereafter. Give dexamethasone 30 minutes to 4 hours before carfilzomib and 1 to 3 hours before IV daratumumab and hyaluronidase-fihj.
For once-weekly 20/70 mg/m2 regimen, give as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day cycle in combination with subcut daratumumab and hyaluronidase-fihj, and dexamethasone until disease progression or unacceptable toxicity occurs. Initially, give 20 mg/m2 on cycle 1, day 1. If tolerated, escalate to 70 mg/m2 on cycle 1, day 8 and thereafter. Give dexamethasone 30 minutes to 4 hours before carfilzomib and 1 to 3 hours before IV daratumumab and hyaluronidase-fihj.
Adjust-a-dose: Refer to the manufacturer's instructions for daratumumab and hyaluronidase-fihj for dosage information.
Released: February 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
clindamycin phosphate
Xaciato
Pharmaceutical company: Daré Biosciences
NEW FORMULATION
Gel: 2%
INDICATION & DOSAGE
Bacterial vaginosis
Adults and children age 12 and older: 1 applicatorful vaginally as a single dose.
Released: February 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
elbasvir–grazoprevir
Zepatier
Pharmaceutical company: Merck Sharp & Dohme Corp
NEW INDICATION & DOSAGE
Chronic hepatitis C virus (HCV) genotypes 1 or 4 infection, with or without ribavirin
Children age 12 and older or weighing at least 30 kg: 1 tablet PO once daily. See manufacturer's instructions for recommended dosing regimens and durations for treatment of HCV genotype 1 or 4 in patients with or without cirrhosis.
Adjust-a-dose: If ALT level is greater than 10 times the upper limit of normal, consider discontinuing the drug. If ALT level is elevated and accompanied by signs or symptoms of liver inflammation, increased conjugated bilirubin or alkaline phophatase level, or increased INR, discontinue the drug. If creatinine clearance is 50 mL/minute or less and ribavirin is used, refer to ribavirin prescribing information for ribavirin dose adjustment.
Released: February 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
pembrolizumab
Keytruda
Pharmaceutical company: Merck & Co.
NEW INDICATION & DOSAGE
Adjuvant treatment of melanoma with lymph node involvement after complete resection
Children age 12 and older: 2 mg/kg IV over 30 minutes every 3 weeks up to maximum dose of 200 mg. Continue until disease recurrence or unacceptable toxicity occurs, or up to 12 months in patients without disease recurrence.
Released: February 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
rituximab
Rituxan
Pharmaceutical company: Genentech
NEW INDICATION & DOSAGE
Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia in combination with chemotherapy
Children age 6 months and older: 375 mg/m2 IV infusion in combination with systemic Lymphome Malin B chemotherapy. Give the drug on day 2 and day 1 (48 hours apart) of each of the induction courses, and on day 1 of each of the two consolidation courses. Give prednisone component of regimen before rituximab. Refer to the manufacturer's instructions for additional dosing information.
Released: February 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
tofacitinib
Xeljanz and Xeljanz XR
Pharmaceutical company: Pfizer
NEW INDICATION & DOSAGE
Ankylosing spondylitis after inadequate response or intolerance to one or more tumor necrosis factor blockers
Adults: 5 mg (immediate-release) PO twice daily. Or, 11 mg (extended-release) PO once daily.
Adjust-a-dose: Reduce dosage to 5 mg (immediate-release) PO daily in patients with moderate to severe renal impairment or moderate hepatic impairment in those receiving concurrent potent CYP3A4 inhibitors, and in those receiving a moderate CYP3A4 inhibitor with a strong CYP2C19 inhibitor.
Released: February 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer